IndustryCompany release

Rigel lifts 2026 revenue outlook as VEPPANU launch adds $6.6M in third quarter

🇺🇸 Rigel Pharmaceuticals Inc (RIGL) · Thu 05 Nov 2026

Rigel Pharmaceuticals reported Q3 net income of $13.2 million and raised its full-year revenue guidance after the US launch of VEPPANU, the first FDA-approved PROTAC.

Rigel Pharmaceuticals reported its third-quarter 2026 results on 5 November, posting net income of $13.2 million and net product sales of $72.3 million. The company's headline revenue figure for the quarter was $80.9 million.

Product sales included $6.6 million from VEPPANU (vepdegestrant), which launched in the US on 13 August. The drug is described as the first FDA-approved PROTAC, a protein-degrading class of medicine. It is indicated for ER+/HER2-, ESR1-mutated advanced breast cancer.

Following the results, Rigel raised its 2026 revenue outlook to roughly $290 million to $295 million.

Separately, Rigel's partner Knight obtained approval from Colombia's drug regulator INVIMA for TAVALISSE in chronic immune thrombocytopenia (ITP).

What it means for your team

  • VEPPANU's launch marks the first commercial test of an FDA-approved PROTAC, a class that regulatory and market-access teams may increasingly encounter.
  • Early sales of $6.6 million cover only the period from the 13 August launch to the end of the quarter, so uptake trends remain to be established.
  • The INVIMA approval of TAVALISSE for chronic ITP, via partner Knight, extends the product's availability in Latin America.
  • The 2026 revenue guidance of about $290-295 million gives a reference point for the company's commercial expectations.

Company's press release (SEC filing): Rigel Pharmaceuticals Inc ↗

Article written by VigiEye from the official source (Rigel Pharmaceuticals Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →